Abstract
INTRODUCTION
Cost variability after lung resection has been recently investigated in the attempt to identify groups of patients in which to improve their pathways of care and ultimately save money [1] [2] [3] . It is well known that the occurrence of postoperative complications with the attending increase in resource utilization and prolonged hospital stay is the principle factor affecting costs following surgery [4, 5] . However, only 20-30% of all patients undergoing to lung resection will develop complications. The majority will have an uneventful postoperative course. The advent of video-assisted thoracoscopic surgery (VATS) for performing major anatomic lung resections has reduced the incidence of complications even more [6, 7] . If every effort should be done to minimize the occurrence of complications by improving standards of care and patient selection, we should not forget that the majority of patients will never experience major postoperative complications. They represent the larger volume of patients and as such the main hospital cost driver.
The identification of cost variability of patients not experiencing major complications will help to streamline care in selected groups with certain characteristics with the aim to improve their care and reduce costs.
Therefore, the objective of this study was to verify postoperative cost variability following anatomic lung resections without major complications and to identify factors associated with increased costs in this group of patients.
PATIENTS AND METHODS
This is a retrospective analysis on prospectively collected data of 250 consecutive patients submitted to anatomic lung resections (224 lobectomies, 15 pneumonectomies and 11 segmentectomies) performed in a single-centre during 1 fiscal year (1 April 2014 -31 March 2015 . One hundred and eighty five resections were performed by VATS.
The study was reviewed by the Research and Innovation Department of the hospital and classified as service evaluation not requiring review by a NHS Research Ethics Committee.
All patients were discussed at a tumour multidisciplinary meeting and inoperability criteria were in accordance with current guidelines [8] .
All patients were operated on by qualified general thoracic surgeons either through a muscle sparing thoracotomy or a 2-3 port VATS.
In general, patients were extubated in the operating room and transferred to a High Dependency Unit (HDU) for the first 24 h. They were then transferred to a dedicated thoracic ward bed when their conditions allowed.
All patients were managed according to standardized pathways of care including pain control (paravertebral and intravenous patient controlled analgesia), early mobilization, chest physiotherapy and rehabilitation and venous thromboembolic prophylaxis.
Fixed, semi-fixed and variable postoperative costs were obtained for each patient from the hospital Patient Level Information and Costing System (PLICS). The system categorises the Trust's costs as either direct, indirect or as an overhead to patient care in accordance with National Health Service (NHS) Clinical Costing Standards. Then by using patient activity-taken from clinical or other data sources, it allocates these costs to each patient in the most appropriate and granular method. This generates a patient bill showing the resources consumed and an actual or calculated cost for the patient episode. Costs were collected in GBP and expressed in Euro (Eur:GBP exchange rate 1.4, as of January 2016).
Fixed costs, such as senior management pay, building overheads and cleaning are allocated in one of two ways. The first method allocates costs to patients in a stepped process, firstly by assigning costs to an area or speciality within the hospital and then to the patients that utilize that area. For example, the cost of a ward stay will include heat and lighting costs for the ward and will be weighted based on the patient's length of stay. Alternatively, fixed costs can be allocated based on the actual usage of a service. For example, actual cleaning hours will be used to allocate a proportion of cleaning costs to individual patients based on their levels of usage.
However, it is the validation and analyses of semi-fixed and variable costs that can inform the differences between pathways of care. These costs may include: radiology and pathology testing, theatre usage, medications, medical staff costs and other specific postoperative therapeutic procedures such as cardioversion, bronchoscopy and blood transfusions. The methods for allocating these costs to patients vary depending on the resource type. Testing costs for example will be directly matched to patients whereas consultant costs will be allocated based on a proportion of their time spent with patients.
A breakdown of the unitary costs used for this analysis is shown in Table 1 .
In most cases, the largest postoperative costs incurred by each patient were the costs of the ward bed they occupied. As these costs vary depending on the patient's length of stay, they can be used as an indication of acuity for each case. Three types of ward have been utilized across the range of cases, a general thoracic ward, a HDU and an Intensive Care Unit (ICU). The predominant ward cost is staffing but also includes running costs such as consumables, drug stock and maintenance costs. Consequently, the average fully absorbed cost for 1 day stay in a general thoracic ward, thoracic HDU bed and ICU is calculated as 418e, 491e and 3060e, respectively.
Thoracic Morbidity and Mortality (TMM) system was used to grade the severity of complications [9] . Regardless the type of complication, the TMM system grades each post-surgical complication in a I to V scale according to the complexity of its management. Grades I and II include minor complications requiring no therapy or pharmacologic intervention only. Grades III and IV are major complications that require surgical intervention or life support. Grade V complications result in patient death as illustrated in Table 2 .
We focused our analysis on 210 patients who did not develop major complications (TMM < 3).
Statistical analysis
The individual line-item costs were summed to obtain the total postoperative cost associated with each patient. The following baseline and surgical variables were tested for a possible association with postoperative costs in patients without major complications by using multivariable regression analysis validated by bootstrap resampling technique: age, sex, body mass index, extent of resection, forced expiratory volume in 1 s (FEV1%), carbon monoxide lung diffusion capacity (DLCO%), moderate to severe chronic obstructive pulmonary disease (COPD) status (FEV1 < 80% and FEV1/FVC ratio < 70%), coronary artery disease (CAD), cerebrovascular disease, diabetes, American Society of Anaesthesiologist (ASA) score, Eastern Cooperative Oncology Group performance score and induction chemotherapy.
For the purpose of developing a user-friendly model, numeric variables were categorized by searching the best threshold value using a c-index analysis.
Multiple regression analysis was then performed by including these categorized variables. Variables with P < 0.05 were retained in the final model and their reliability tested by bootstrap analysis with 1000 samples [10] [11] [12] . In the bootstrap procedure, repeated samples of the same number of observations as the original database were selected with replacement from the original set observations. For each sample, multivariable regression was repeated. Variables occurring in the majority of the bootstrap models (>50%) were judged to be stable and retained in the final model. Finally, a model estimating the postoperative cost based on patient characteristics and type of surgery was developed. The analysis was performed by using the STATA 12.0 (Stata Corp., College Station, TX) statistical software.
RESULTS
Of the total 250 patients submitted to major anatomic resections during the study time, 40 developed major complications (TMM > 2) and were excluded from the analysis.
One hundred and seventeen patients did not develop any complications and 93 patients experienced minor complications (TMM grade 1 or 2).
The most frequent complications classed as minor were the followings: 16 prolonged air leaks, 16 atrial fibrillation, 25 pneumonia, 11 sputum retentions treated with physiotherapy, 4 postoperative delirium, 5 acute kidney failures, 5 ileum, 5 subcutaneous emphysema, 4 urinary tract infections, 4 urinary retentions, 1 wound infection and 6 electrolyte imbalances.
The characteristics of the 210 patients without major complications included in the study are shown in Table 3 .
Patients with minor or no complications had an average postoperative cost of 4040e (range 2205-15 466e), 9000e lower than the cost observed in patients with major complications (13 156e, P < 0.0001). Table 4 shows the breakdown of postoperative costs by TMM class. Patients with complications graded as TMM 2 (pharmacologic treatment only) were 1480e more expensive than those without any complications (P < 0.001).
The higher costs of the patients with minor complications were mainly associated with their longer hospital stays. These patients had an average postoperative stay 6.5 days longer than those without complications (10.7 vs 4.1 days, P < 0.0001).
The results of the stepwise multivariable regression analysis (dependent variable: postoperative cost) are shown in Table 5 .
The presence of CAD (P = 0.004), low DLCO (P = 0.001) and performance of thoracotomy (P = 0.01) instead of VATS were independently and reliably associated with postoperative costs.
The corresponding regression equation to estimate postoperative costs is the following: 5344 + 1131.8XCAD (presence of CAD coded as 1, absence of CAD coded as 0) + 658.6XThoracotomy (presence of thoracotomy coded as 1, absence of thoracotomy coded as 0) -21.6XDLCO.
Variables such as sex, age, FEV1, ECOG score, ASA score, Diabetes, cerebrovascular disease, COPD status, neoadjuvant chemotherapy and extent of resection were not retained in the final model as their P value was lower than 0.05.
DLCO resulted the only significant numeric variable. The best cut-off value associated with postoperative cost resulted 60%.
Multivariable regression was repeated using DLCO < 60% as categorical variable (Table 6 ).
According to the regression model, being submitted to thoracotomy would increase the postoperative cost by 648e, having DLCO < 60% by 935e and having a history of CAD by 1043e. If all three factors were present, an increase of postoperative costs from 3592e (cost of a patient without major complications and without any of the three factors) to 6219e would be expected. The higher postoperative costs observed in patients with one or more of the risk factors can be explained in part by their longer hospital stay compared to those without any of the risk factors (6.1 vs 4.7 days, P = 0.0007). In addition, the proportion of patients with a postoperative stay longer than 7 days was higher in those with at least one risk factor (24%) compared to those without any (11%) (P = 0.01). Patients with no major complications and with a history of CAD had a 1.5 days longer postoperative stay compared to those without CAD (7.6 vs 5.1 days, P = 0.009). Patients with no major complications with a preoperative DLCO < 60% had a 1.7 days longer postoperative stay compared to those with a higher DLCO value (6.7 vs 5.0 days, P = 0.0005). Finally, patients with no major complications submitted to thoracotomy instead of VATS had a 0.9 days longer postoperative stay (6.0 vs 5.1 days, P = 0.09). Interestingly, when all patients with and without major complications were combined, DLCO and CAD lost their association with postoperative costs at regression analysis. Multiple regression analysis performed on all 250 patients showed that presence of diabetes (P = 0.002) and thoracotomy (P = 0.002) remained significantly associated with postoperative costs. The corresponding following cost estimation model was derived for all patients: 4131.4 + 3963XDiabetes (presence of diabetes coded as 1, absence of diabetes coded as 0)+ 3186XThoracotomy (presence of thoracotomy coded as 1, absence of thoracotomy coded as 0).
DISCUSSION

Rationale and objectives
Identification of cost variability amongst patients submitted to lung resection has been a recent focus of investigation. Previous papers have tried to develop financial models adjusted on clinical characteristics and have been able to identify groups of patients or specific comorbidities associated with increased cost after lung resection [1] [2] [3] .
A recent study has shown for instance that although intraoperative costs may be higher than postoperative costs, the latter displayed a much greater variability [3] . Knowing that certain groups of patients are at higher risk of being more expensive than others can trigger in-depth analyses to audit their pathways of care with the final aim to improve their postoperative course, outcome and ultimately save money.
Although previous studies have shown that postoperative costs are mainly related to complications, the majority of patients after lung surgery will not develop major complications. They certainly represent the main financial driver of this operation. For this reason, we wanted to focus our attention on those patients, who did not develop major complications and try to identify factors associated with postoperative costs. In order to classify the severity of complications we used a previously validated system, the TMM classification system [9] . This grading system classifies the severity of the complications based on the complexity of their treatment. Complications managed with observation only or by pharmacologic intervention were classed as minor. The final objective was to develop a financial model able to estimate the postoperative costs in this specific group of patients.
Main findings
One of the main finding of this study was that patients with minor or no complications following lung resection had an average postoperative cost of 4040e, with a large variability. The cheapest patient cost 2205e whereas the most expensive 15 466e, a value 7-fold higher. This result confirmed previous findings. In the paper of Medbery et al. [2] postoperative costs showed the greatest variability ranging from 3000$ to 63 000$ after VATS lobectomy. Similarly, in a previous paper from our group [3] , the variability of the postoperative costs was much larger than the intraoperative costs (from 530e to 53 000e). It appears clear that there are margins of saving by improving the care of those patients with the highest cost.
The use of multivariable regression analysis showed that some clinical factors were significantly associated with postoperative cost.
A history of CAD, a low DLCO and performance of thoracotomy instead of VATS increased the risk of having an expensive postoperative course.
Patients with one or more of these risk factors had longer postoperative stays and this explains in part their increased costs.
The presence of CAD and a low DLCO were found associated with postoperative costs in previous studies [2, 3] . Their association with cost appears logical since they are factors reputedly linked with increased risk of complications. The novel finding in this study was that these risk factors were also associated with increased costs in those patients with minor complications only or without complications. A possible explanation of this finding can be that the presence of CAD or low DLCO may increase the risk of complications such as AF, pneumonia or prolonged air leak, which are mostly managed without any major procedure or with pharmacologic intervention only (TMM class 1 or 2). Despite being classed as minor complications they can contribute to prolong hospital stay and increase cost.
For the same reason, patients operated on by VATS experienced a shorter hospital stay, probably for a lower incidence of minor complications or less postoperative pain. This translated into a lower cost compared to patients operated on by thoracotomy. This finding confirmed previous studies showing the postoperative financial benefits of VATS over thoracotomy [13] [14] [15] [16] . We were able to show this financial benefit also in patients without major postoperative complications.
According to our analysis, a patient with an uneventful course submitted to thoracotomy would have an expected postoperative cost 648e higher than if operated on by VATS.
Limitations
This study may have several potential limitations.
The risk adjusting cost analysis refers only to patients submitted to anatomic lung resection and who did not experience major complications. The model is not valid for those patients experiencing major complications, who are expected to have higher costs and for other types of operations (as patients will likely have different case mixes).
Dichotomization of numeric factors in the aggregate model to estimate costs may have inherent downsides such as imprecision in cost estimation. Nevertheless, we performed this categorization only after having run the regression analysis keeping all numeric variables as continuous. DLCO resulted significant and reliable when used as continuous variable and was categorized only post hoc to produce a more user-friendly model.
The financial data used in this study has been derived from the Trust's new PLICS system, which was implemented from March 2015 onwards. The main methodologies used to allocate costs in PLICS have been validated with the input of clinical, financial and managerial staff. However, the validation of outputs is inevitably an on-going process that will require further clinical review and discussion to improve the accuracy, robustness and confidence in the data produced.
Cost accuracy is also dependent upon the level of costs that can be allocated using electronic feeds that capture the resources actually consumed by identifiable patients, which otherwise would be allocated using an appropriate apportionment methodology. Even where electronic sources are available, poor data quality may limit their usefulness within PLICS (for example, if patient identifiers are not correctly recorded). The process of validation should therefore focus attention on the way information is recorded and coded across the organization, helping to improve the quality and variety of data that is inputted into the system. This will reduce the need to use manufactured methodologies to allocate costs to patients and add layers of granularity to the information that PLICS produces. Notably this includes advances in initiative aimed at developing a patient barcoding system, which will allow instant tracking of consumables to the patients that have used them. In addition, refinement in hospital stay cost, which would take into consideration a cost variability proportional with the duration of stay assuming a progressively lower intensity of care may help in the future to improve the cost model.
Our hospital has a high patient volume, allowing negotiable high discounts of consumables, which may not be reproducible in other settings.
This study only looked at the hospital postoperative costs associated with lung resections and did not capture the entire episode of care, including readmissions, emergency room visits, postoperative clinic visits and home care. Such financial information was not available at the time of this study. Therefore, our financial figures represent only a portion of the entire postoperative care episode.
Future analyses will be needed to evaluate and risk adjust the costs associated with the other elements, since they will be utilized in future bundled payment arrangements.
Clinical and research implications
The knowledge that certain patient characteristics or certain types of operation, independently by the occurrence of major complications, are associated with increased postoperative costs may have important clinical and managerial implications. This information may be used to assess the financial performance of specific surgical services and to define more precisely the required investments and resources utilization during the annual budget discussion. The use of a cost model such as the one derived from this analysis fits in the conceptual framework of the accountable care organizations. Providers have both financial and clinical accountabilities. They are responsible to deliver high quality outcomes and reduce total cost of care for specific population of patients. Furthermore, the model proposed in this study represents a further methodological template, which can be used by health administrators and regulators to redefine reimbursement tariffs for specific groups of patients with certain characteristics.
Finally, the identification of CAD, low DLCO and thoracotomy as factors associated with postoperative costs should prompt root cause analyses to identify the cause of the increased costs in these groups of patients with the aim to improve their pathways of care, reduce cost variability and ultimately save money.
Future research is needed to evaluate whether the institution of specific measures or processes of care would lead to a reduction in cost variability in these classes of patients.
